At Bombay House, the storied headquarters of one of India's oldest and most consequential business empires, a quiet constitutional order is fracturing. The board of Tata Sons has reappointed its chairman and embraced a public listing, directly defying Tata Trusts — the charitable majority shareholder whose dividends sustain hospitals and universities — which has declared both moves illegal. What is unfolding is not merely a corporate dispute but a collision between two visions of what a great institution owes to the public: transparency and market accountability on one side, and the patient, p